UiPath Stock Slides 27% YTD: Is PATH a Buy, Hold, or Sell?

UiPath reported Q1 fiscal 2027 revenue growth of 17% year over year, with non-GAAP operating income of $92 million and adjusted free cash flow of $130 million, underscoring improving profitability and cash generation. However, management and analysts still see AI monetization as early-stage, with Q2 fiscal 2027 EPS expected to decline 6.7% to $0.14 even as revenue is projected to rise 9.9% to $397.6 million. The stock remains under pressure, down 27% year to date, and the article frames PATH as a Hold amid rising competition from Microsoft and ServiceNow.

Analysis

PATH looks less like a broken growth story and more like a re-rating problem: the market is demanding proof that AI attachment rates can translate into faster net retention and seat expansion, not just strategic relevance. The key second-order effect is that orchestration is a winner-take-most control point; if UiPath becomes the governance layer across heterogeneous models and agents, switching costs can rise materially even if top-line growth only stays mid-teens. The risk is that this thesis takes multiple quarters to monetize because procurement, compliance and workflow redesign all lag product innovation.

Competitive pressure is the main reason the stock can stay cheap. NOW and MSFT can bundle automation into broader enterprise relationships, which means UiPath may need to spend more on sales coverage and product breadth just to defend share, pressuring operating leverage later in the year. That said, the more Microsoft embeds low-code/AI tools into general-purpose workflows, the more it creates an opening for a neutral orchestration layer in regulated enterprises that do not want to be locked into a single cloud stack.

The setup is best viewed as a catalyst-driven hold-to-better-long. Near term, the stock likely trades on evidence of AI-driven expansion in large accounts and whether guidance inflects above the current 8-10% revenue growth band; without that, multiple expansion is capped. The contrarian miss is that consensus is treating PATH as if AI monetization is binary, when the more important variable is gradual dollar-based expansion in a sticky installed base that can support margin expansion before headline growth re-accelerates.

Key Decisions for Investors

• Maintain/initi ate a small tactical long PATH only on a post-earnings selloff, with a 3-6 month horizon; risk/reward improves if the stock de-risks on muted guidance and the market is underestimating FCF durability.
• Use a pair trade: long PATH / short NOW over 2-4 quarters if you believe orchestration-specific demand will outperform broader workflow software; expect PATH to lag on quality metrics but outperform if AI attach rates surprise upward.
• For lower-risk expression, buy PATH call spreads 6-9 months out rather than stock; upside is tied to a re-rating on proof of AI monetization, while downside remains bounded if growth stays merely steady.
• Avoid chasing MSFT or NOW as 'AI automation' proxies here; they are better financed competitors and likely suppress PATH multiple expansion unless UiPath demonstrates clear product differentiation in regulated workflow orchestration.
• Set a downside trigger: if next two quarters show revenue growth decelerating below ~10% or FCF conversion weakens, exit long exposure and consider a short into the next guide-down cycle.